MILLENIA HOPE INC.
        (Exact name of Small Business Issuer as Specified in its Charter)


            DELAWARE                                     98-0213828
(state or other Jurisdiction of                       (I.R.S Employer
 Incorporation or Organization)                      Identification No.)


           4055 Ste Catherine st. suite 142, Montreal, Quebec H3Z 3J8
                    (Address of Principal Executive Offices)


                                 (514) 846-5757
                 Issuer's Telephone Number Including Area Code)


State the number of shares outstanding of each of the issuer's classes of common
equity,  as of the latest  practicable  date:  At  February  29, 2000 Issuer had
outstanding 10,774,220 shares of Common Stock.

<PAGE>


                                      INDEX

PART I:   FINANCIAL INFORMATION


     Item 1.   Financial Statements

               Balance Sheet (Unaudited) at February 29, 2000.

               Statement of  operations  (Unaudited)  for the three months ended
               February  29,  2000 and  February  28,  1999  and from  inception
               (December 24, 1997) to February 29, 2000.

               Statements of cash flows  (Unaudited)  for the three months ended
               February  29,  2000 and  February  28,  1999  and from  inception
               (December 24, 1997) to February 29, 2000.

               Notes to the Financial Statements (Unaudited)

     Item 2.   Plan of Operations


PART II.  Other Information

     Item 2.   Sale of Unregistered Securities

     Item 6.   Exhibits and Reports on Form

     SIGNATURES

<PAGE>


                               MILLENIA HOPE INC.
                      (A COMPANY IN THE DEVELOPMENT STAGE)
                                  BALANCE SHEET
                                AT FEBRUARY 29, 2000
                                   (UNAUDITED)



                                     Assets
                                     ------

Current Assets
     Cash and cash equivalents                                           $ 5,663
                                                                         -------

       Total current assets                                                5,663
Property and equipment, net                                               42,722
                                                                         -------

       Total assets                                                       48,385
                                                                         =======




                      Liabilities and Shareholder's Equity
                      ------------------------------------

Current Liabilities
     Accounts payable and accrued liabilities                           196,153
       Other current liabilities                                         20,350
                                                                    -----------

       Total current liabilities                                        216,503

 Shareholder's Equity
     Common Stock, $.0001 par value; authorized                           1,077
          70,000,000 shares; issued and outstanding 10,774,220
     Warrants                                                         1,393,247
     Paid in Capital                                                  2,010,908
     Cost of Treasury Shares                                                100
     Deficit accumulated during the development stage                (3,573,450)
                                                                    -----------

       Total Shareholder's Equity                                      (168,118)

        Total liabilities and shareholder's equity                  $    48,385
                                                                    ===========

                         Read the accompanying notes to
  financial statements, which is an integral part of this financial statement.

<PAGE>


                               MILLENIA HOPE INC.
                      (A COMPANY IN THE DEVELOPMENT STAGE)
                             STATEMENT OF OPERATIONS
         FOR THE 3 MONTHS ENDED FEBRUARY 29, 2000 AND FEBRUARY 28, 1999
                    (UNAUDITED) AND THE PERIOD FROM INCEPTION
                   (DECEMBER 24, 1997) TO FEBRUARY 28, 2000.


<TABLE>
<CAPTION>
                                                                                                          INCEPTION
                                                                      3 months ended                    (Dec. 24, 1997)
                                                           Feb. 29, 2000          Feb 28, 1999           Feb.29, 2000
                                                         ----------------       ----------------       ----------------
<S>                                                      <C>                    <C>                    <C>
Revenue:
       Licensing fees                                    $          7.500       $          5.000       $         35.000

Operating expenses:
       Marketing                                                       --                     --              1.514.215
       Patent Rights                                                   --                     --              1.005.827
       Other Development Costs                                         --                     --                218.515
       Travel                                                          --                     --                122.000
       Rent                                                        19.100                 19.100                156.750
       Selling, general and administrative expenses                29.502                  9.860                441.505

          Total operating expenses                                 48.602                 33.960              3.458.812

          Loss before other income (expense)                      (41.102)               (28.960)            (3,423,812)

Other income (expense):
       Interest expense                                           (27.770)               (16.458)              (149.639)

          Total other income (expense)                            (27.770)               (16.458)              (149.639)

Net Loss                                                          (68.872)               (45.418)            (3,573,451)
                                                         ================       ================       ================

Basic weighted average common shares outstanding                10,992,72             10,100,000             10.734.308
                                                         ================       ================       ================

Basic Loss per common share                              $        (0.0063)      $        (0.0045)      $        (0.3329)
                                                         ================       ================       ================
</TABLE>


Read the accompanying notes to financial  statements,  which is an integral part
of this financial statement.

<PAGE>


                               MILLENIA HOPE INC.
                      (A COMPANY IN THE DEVELOPMENT STAGE)
                             STATEMENT OF CASH FLOWS
         FOR THE 3 MONTHS ENDED FEBRUARY 29, 2000 AND FEBRUARY 28, 1999
                        AND THE PERIOD FROM THE INCEPTION
                    (DECEMBER 24, 1997) TO FEBRUARY 29, 2000
                                   (UNAUDITED)


<TABLE>
<CAPTION>

                                                                                                                  Inception
                                                                                       Three Months          (December 24, 1997)
                                                                                      Ended February 29,           through
                                                                      ------------------------------------
                                                                           2000              1999             February 29, 2000
                                                                      ---------------   ---------------   -------------------------
<S>                                                                        <C>               <C>                      <C>
CASH FLOWS FROM OPERATING ACTIVITIES:

Net Income (Loss)                                                          $ (68,872)        $ (40,418)               $ (3,573,450)
Adjustments to reconcile net income (loss) to net cash
used in operating activities:
             Depreciation and amortization                                     3,514             3,641                      33,278
             Issuance of stock for marketing services                              -                 -                   1,514,215
             Issuance of note for other development costs                          -                 -                     192,831
             (subsequently converted to warrants)
             Interest expense settled with issuance of note                   27,770                 -                      27,770
             (subsequently converted to warrants)
Changes in Operating assets and liabilities:
             Accounts Payable and Accrued Liabilities                         39,853           (65,026)                    216,503
                                                                      ---------------   ---------------   -------------------------

Net cash provided by/(used in) operating activities                            2,265          (101,803)                 (1,588,853)


CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of Property and equipment                                                 -                 -                     (76,000)
                                                                      ---------------   ---------------   -------------------------

Net cash provided by/(used in) investing activities                                -                 -                     (76,000)


CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from:
  Notes payable, principally related parties (net of discount)               (51,205)           89,878                   1,172,648
  Issuance of stock                                                           50,670                 -                     497,870
                                                                      ---------------   ---------------   -------------------------

Net cash provided by/(used in) financing activities                             (535)           89,878                   1,670,517
                                                                      ---------------   ---------------   -------------------------


Net increase (decrease) in cash and cash equivalents                           1,730           (11,925)                      5,663
Cash and cash equivalents, beginning of period                                 3,933            21,000                           -
                                                                      ---------------   ---------------   -------------------------

Cash and cash equivalents, end of period                                     $ 5,663           $ 9,075                     $ 5,663
                                                                      ===============   ===============   =========================
</TABLE>


Supplemental Schedule of noncash investing and financing activities:

On February  28,  2000,  the  company  issued  4,644,156  warrants to settle the
following related party notes:

    Notes payable (principally related parties) (net of discount)      1,172,648
    Long -term debt, less current portion (net of discount)              104,031
    Current portion of long term debt ( net of discount)                  88,800
    Current year interest expense                                         27,770
                                                                     -----------
                                                                       1,393,249


<PAGE>


                               MILLENIA HOPE INC.
                      (A COMPANY IN THE DEVELOPMENT STAGE)
                 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

                                   (Unaudited)

                                FEBRUARY 29, 2000




NOTE 1 -BASIS OF PRESENTATION

     The accompanying  unaudited  consolidated  financial statements of Millenia
Hope Inc. have been prepared in accordance  with generally  accepted  accounting
principles for interim  financial  information and with the instructions to Form
10-QSB and Article 10 of Regulation  S-X. The financial  statements  reflect all
adjustments  consisting of normal recurring adjustments which, in the opinion of
management, are necessary for a fair presentation of the results for the periods
shown.  Accordingly,  they do not include all of the  information  and footnotes
required by generally  accepted  accounting  principles  for complete  financial
statements.

     These financial  statements  should be read in conjunction with the audited
financial  statements  and  footnotes  thereto  included in Millenia Hope Inc.'s
Registration  Statement on Form 10SB  (Registration No. 000-29385) as filed with
the Securities and Exchange Commission.

     The  preparation  of financial  statements  in  conformity  with  generally
accepted  accounting  principles  requires  management  to  make  estimates  and
assumptions  that  affect the  reported  amounts of assets and  liabilities  and
disclosure of  contingent  assets and  liabilities  at the date of the financial
statements and that effect the reported  amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates.


NOTE 2 - REVENUE RECOGNITION

    The    company    currently    recognizes    revenue    in   the   form   of
licensing/distributor  fees which are  recorded  over the life of the  licensing
agreement  using  the  straight  line  method.  Currently  the  company  has one
agreement with a term of 5 years commencing on January , 1999.

    In December  1999, the  Securities  and Exchange  Commission  ("SEC") issued
Staff  Accounting  Bulletin No. 101 ("SAB 101"),  "Revenue  Recognition,"  which
provides guidance on the recognition,  presentation and disclosure of revenue in
financial  statements  filed with the SEC. SAB 101  outlines the basic  criteria
that must be met to  recognize  revenue and  provide  guidance  for  disclosures
related to revenue recognition policies.  Management believes that Millenia Hope
Inc.'s revenue  recognition  practices are in conformity  with the guidelines of
SAB 101.

NOTE 3 - NET LOSS PER SHARE

     Basic  earnings  (loss) per share is  computed  using the  weighted-average
number of common shares outstanding during the period.  Options and warrants are
not considered since considering such items would have an antidilutive effect.

NOTE 4 - GOING CONCERN

     The  accompanying  financial  statements  have been  prepared  assuming the
Company will  continue as a going  concern.  The company  reported a net loss of
$68,872 for the three  months ended  February 29, 2000 as well as reporting  net
losses of $3,573,450 from inception (December 24, 1997) to February 29, 2000. As
reported on the  statement of cash flows,  the Company  incurred  negative  cash
flows from  operating  activities of  $1,588,853  from  inception  (December 24,
1997).  To date,  these  losses and cash flow  deficiencies  have been  financed
principally  through  the sale of common  stock  ($497,870)  and short term debt
($1,172,648)  which is related party debt.  Additional capital and/or borrowings
will be  necessary  in order for the  Company to  continue  in  existence  until
attaining and  sustaining  profitable  operations.  Management  has continued to
develop a  strategic  plan to  develop a  management  team,  maintain  reporting
compliance and establish long term relationships with other major  organizations
to develop and distribute the product Malarax. Management anticipates generating
revenue  through  the sales of Malarax  during the next fiscal  year.  The major
shareholder's of the  organization  have committed to fund the operations of the
organization  during the next fiscal year until the  organization  can  generate
sufficient  cash flow from  operations  to meet current  operating  expenses and
overhead.


NOTE 5 - STOCKHOLDER'S EQUITY

      In  February  1998,  the  company  issued in  accordance  with it  private
placement  offering exempt from registration  requirements under section 4(2) of
the  Securities  Act of 1933,  as  amended,  and Rule 504 of  Regulation  D sold
6,100,000  units (each unit  consisting  of one (1 share of common stock and (1)
warrant) at a price of $0.07 per unit.  Each  warrant  entitles  the  registered
holder  thereof to purchase at any time from the date of the offering  until the
close of business  February  11,  2001,  one share of common stock at a price of
$0.09. On January 17, 2000, the company issued 563,000 shares of common stock at
a price of $0.09 per share to individuals who exercised their warrants.

On February 28, 2000, the company issued 4,644,156 warrants to settle the
following related party notes:
Current portion of long term debt (net of discount)            $   88,800
Notes payable (principally related parties)(net of discount)    1,172,648
Long-term debt, less current portion (net of discount)            104,031
Current year interest expense                                      27,770
                                                               ----------
                                                               $1,393,249
                                                               ==========

     On January 20, 2000, one of the founders of the corporation who was invited
to participate at the inception of the corporation  based upon on his ability in
the area of  investor  relations  agreed to return his  1,000,000  shares to the
company for cancellation  due to changed personal  circumstances in which he was
unable to devote  significant time and effort to the company.  These shares have
been classified as treasury shares.


<PAGE>


Item 2. Plan of Operation.

The  following  discussion  should  be read in  conjunction  with the  financial
statements  and related notes which are included  elsewhere in this  prospectus.
Statements  made  below  which  are not  historical  facts  are  forward-looking
statements.   Forward-looking   statements   involve   a  number  of  risks  and
uncertainties including, but not limited to, general economic conditions and our
ability to market our product.

Some of the statements  hereunder are  forward-looking  statements  that involve
risks and  uncertainties.  These  forward-looking  statements include statements
about our plans, objectives, expectations,  intentions and assumptions and other
statements  contained herein that are not statements of historical fact. You can
identify these statements by words such as "may," "will," "should," "estimates,"
"plans," "expects,"  "believes,"  "intends" and similar  expressions.  We cannot
guarantee future results, levels of activity,  performance or achievements.  Our
actual  results and the timing of certain events may differ  significantly  from
the results discussed in the forward-looking  statements.  You are cautioned not
to place undue reliance on any forward-looking statements.

The business objectives of Millenia are twofold.

First and foremost is to establish  MALAREX as an accepted control agent for the
treatment and prevention of malaria throughout the world. Not only do we believe
that MALAREX is an effective  anti-malarial drug, it will also be made available
at prices  that are adapted to the  realities  of the third  world  market.  The
availability and pricing of MALAREX will hopefully ensure its  acceptability and
use in the fight  against  malaria.  To this end the company  has  entered  into
clinical trials of MALAREX with the following three countries:

o    On October 5th, 1999 India's  Directorate  of Health  accepted  MALAREX for
     both in-vitro  (test-tube) and in-vivo (live trials)  testing.  On February
     28th, 2000 the in-vitro tests were  successfully  completed and the in-vivo
     tests are scheduled to be run next.

o    On January 13th, 2000 Cameroun's  Department of Health accepted MALAREX for
     both  in-vitro and in-vivo  testing.  As of February  17th,  2000 the above
     testing was  successfully  concluded.  The company is waiting for the final
     approval of the  Department  of Health for MALAREX to be sold in  Cameroun.
     Management  believes that sales of MALAREX should  commence within the next
     six months in Cameroun.

o    On January  26th,  2000 the  Ministry of Health and  Welfare of  Equatorial
     Guinea  accepted  MALAREX  for both  in-vitro  and in-vivo  testing.  As of
     February 27th, 2000 the in-vitro testing was successfully  concluded and we
     are  waiting  for the  in-vivo  testing  to be  concluded.  If this step is
     successful  then final approval of the ministry of Health and Welfare would
     be needed to commence sales of MALAREX.

Millenia has adopted an extremely  conservative  sales forecast.  In the face of
anti-malarial  drug  resistance,  the need for more  effective  treatments  will
continue to intensify.  Once a network of local  manufacturers  and distributors
capable of producing and supplying  MALAREX are in place, the demand for MALAREX
should increase commensurately.

<PAGE>


It is estimated  the demand for MALAREX will  increase as it becomes an accepted
choice in the fight against malaria.  Once it has proven its  effectiveness  and
availability,  it could be among the leaders in the field. Despite this positive
conviction,  Millenia chooses to remain  conservative in its sales estimation as
it strives to attain its goal of 2 % of the marketplace in five years.

Achieving  these modest levels will ensure both the viability and  profitability
for both the Company and its shareholders.

Secondly,  Millenia is committed to ongoing  research and  development to expand
the efficacy of MALAREX and its derivatives in fighting infectious diseases.  To
this end,  the  company has a verbal  agreement  with one of its  officers,  Mr.
Guiseppe  Bertelli Motta,  VP of research and a  co-discoverer  of MALAREX whose
profession is botanical  research,  that it will have the first right of refusal
on all the research  carried on by him. As cash flow improves,  further  funding
will be commited to research and development.

As an integral part of this  development,  Millenia hopes to establish long term
relationships  with other major  organizations  such as Rotary  Against  Malaria
(RAM),  World Health  Organization and the Centers for Disease  Controls.  It is
through these  relationships  that Millenia feels that they can best support the
efforts of such  organizations  to solve the  problem of malaria by  building an
infrastructure necessary to control this disease.

As the  Company  has not yet  begun to sell the  Product,  it is  difficult  for
management  to evaluate the growth curve of Product  sales.  However,  given the
potential  market size and the need for viable and effective  drugs, the Company
believes  that it will not have a  problem  generating  sales  thereby  creating
positive cash flow once the Product is approved.

The Company intends to use the Internet for advertising as that currently allows
the greatest visibility for very small costs. In fact, the Company believes that
it will be able to obtain free access on certain  websites  looking for products
such as the Company's.

At present the only  significant  cash outlay of the Company is for rent as well
as legal and accounting  fees incurred by the Company as it prepares this filing
and filings  associated  with being a  reporting  company  (quarterly  unaudited
reports,  annual  reports,  etc.).  There  is  currently  insufficient  funds to
adequately provide for the Company's needs over the next twelve months, however,
the officers and certain  shareholders  have committed to fund the operations of
the  company  during  the net  twelve  months  until the  company  can  generate
sufficient  cash flow from  operations  to meet current  operating  expenses and
overhead.

Liquidity and cash flow needs of the company

From December 1st, 1999 to February 28th,  2000 the company  incurred  operating
expenses  of $ 41,102 and  interest  expenses  in the  amount of  $27,770  while
recording  net cash revenues of $7,500.  From March 1st, 2000 to November  30th,
2000, the fiscal year end, the company  anticipates that its net cash flow needs
will be $123,000 primarily to cover day to day operating  expenses.  These funds
will be  covered  by  revenue  received  and any  shortfalls  will be met by the
officers and certain shareholders as previously outlined.

<PAGE>


On February 22, 2000 Dr. David Mulder  joined the Board of Directors of Millenia
Hope as its Vice-Chairman of the Board. Dr Mulder, a physician with expertise in
several  disciplines,  was the former chairman of Montreal's  McGill  University
department of surgery and the  surgeon-in-chief at the Montreal General Hospital
for 21 years. Dr Mulder has held leading  positions in several important medical
associations,  including  presidency  of the  Canadian  Association  of Thoracic
Surgeons and the Canadian Surgical Association.

The Company intends to continue  conducting  product research and development as
mentioned  previously.  The Company  will, in the future,  retain  marketing and
public relations consultants as necessary, and hire support staff when warranted
by its sales volume on an as needed basis.

<PAGE>


Part II other information

Item 2: Sales of Unregistered securities


Date of      Title of        Number       Consideration     Exemption from
Sale         Security        Sold         Received          Registration claimed

1/17/2000    Common            563,000    $ 50,670          Regulation  S
             Shares

2/28/2000    Warrants        4,644,156    conversion of     Regulation  S
             exercisable                  $ 1,393,247
             at $1.00 per                 of debt
             share until
             11/30/2002

<PAGE>


ITEM 6: EXHIBITS AND REPORTS ON FORM 8-K

(a)  Exhibits

     27.  Financial Data Schedule (2/29/00)

(b)  Reports on Form 8-K

     None

<PAGE>


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.



                                        Millenia Hope Inc.
                                        (Registrant)



Dated: April 14, 2000                   By:  /s/ Leonard Stella
                                             -----------------------
                                             President and Treasurer